Predicting Virological Response to HIV Treatment Over Time: A Tool for Settings With Different Definitions of Virological Response.


Journal

Journal of acquired immune deficiency syndromes (1999)
ISSN: 1944-7884
Titre abrégé: J Acquir Immune Defic Syndr
Pays: United States
ID NLM: 100892005

Informations de publication

Date de publication:
01 06 2019
Historique:
pubmed: 14 3 2019
medline: 25 2 2020
entrez: 14 3 2019
Statut: ppublish

Résumé

Definitions of virological response vary from <50 up to 1000 copies of HIV-RNA/mL. Our previous models estimate the probability of HIV drug combinations reducing the viral load to <50 copies/mL, with no indication of whether higher thresholds of response may be achieved. Here, we describe the development of models that predict absolute viral load over time. Two sets of random forest models were developed using 50,270 treatment change episodes from more than 20 countries. The models estimated viral load at different time points following the introduction of a new regimen from variables including baseline viral load, CD4 count, and treatment history. One set also used genotypes in their predictions. Independent data sets were used for evaluation. Both models achieved highly significant correlations between predicted and actual viral load changes (r = 0.67-0.68, mean absolute error of 0.73-0.74 log10 copies/mL). The models produced curves of virological response over time. Using failure definitions of <100, 400, or 1000 copies/mL, but not 50 copies/mL, both models were able to identify alternative regimens they predicted to be effective for the majority of cases where the new regimen prescribed in the clinic failed. These models could be useful for selecting the optimum combination therapy for patients requiring a change in therapy in settings using any definition of virological response. They also give an idea of the likely response curve over time. Given that genotypes are not required, these models could be a useful addition to the HIV-TRePS system for those in resource-limited settings.

Identifiants

pubmed: 30865186
doi: 10.1097/QAI.0000000000001989
doi:

Substances chimiques

Anti-Retroviral Agents 0
RNA, Viral 0

Types de publication

Journal Article Research Support, N.I.H., Extramural

Langues

eng

Sous-ensembles de citation

IM

Pagination

207-215

Auteurs

Andrew D Revell (AD)

The HIV Resistance Response Database Initiative (RDI), London, United Kingdom.

Dechao Wang (D)

The HIV Resistance Response Database Initiative (RDI), London, United Kingdom.

Maria-Jesus Perez-Elias (MJ)

Servicio de Enfermedades Infecciosas, Hospital Ramón y Cajal, Madrid, Spain.

Robin Wood (R)

Desmond Tutu HIV Centre, University of Cape Town, Cape Town, South Africa.

Hugo Tempelman (H)

Ndlovu Care Group, Elandsdoorn, South Africa.

Bonaventura Clotet (B)

Institut de Recerca de la Sida, IrsiCaixa, Hospital Universitari Germans Trias i Pujol, Barcelona, Spain.

Peter Reiss (P)

Amsterdam Institute for Global Health and Development, Amsterdam, the Netherlands.
Stichting HIV Monitoring, Amsterdam, the Netherlands.

Ard I van Sighem (AI)

Stichting HIV Monitoring, Amsterdam, the Netherlands.

Gerardo Alvarez-Uria (G)

Rural Development Trust (RDT) Hospital, Bathalapalli, India.

Mark Nelson (M)

Chelsea and Westminster Hospital, London, United Kingdom.

Julio S G Montaner (JSG)

BC Centre for Excellence in HIV/AIDS, St. Paul's Hospital, Vancouver, British Columbia, Canada.

H Clifford Lane (HC)

National Institute of Allergy and Infectious Diseases, Bethesda, MD.

Brendan A Larder (BA)

The HIV Resistance Response Database Initiative (RDI), London, United Kingdom.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH